Yu-Ming Chang, Chairman of Myson Century, stated on the 19th that the company will focus on healthcare, AI technology, and precision data applications to drive the deep integration of health management and intelligent applications. The company aims to build an "AI Smart Health" ecosystem while integrating insurance and financial services, initiating a major strategic upgrade. With this transformation, Myson Century anticipates quarterly growth throughout the year, potentially achieving a twofold increase in revenue, with the health supplements segment expected to account for over 50% of total revenue.
Additionally, during its extraordinary shareholders’ meeting in January, Myson Century approved a stock split plan, where one share will be split into 20 shares. Based on the closing price of NT$814 on the 19th, the post-split price per share is estimated to be around NT$40, with the split expected to be completed by the end of March.
For the first three quarters of last year, Myson Century reported an earnings per share (EPS) of NT$9.56. Due to a surge in health supplement sales in Q4, the company saw strong profit momentum, and market analysts estimate full-year EPS to range between NT$15 and NT$18. The company has also revealed that its dividend policy will include a combination of cash and stock dividends.
In 2023, Myson Century achieved revenue of NT$644 million, marking a 659.47% year-over-year growth. The health supplements segment’s revenue share increased significantly from 11% at the beginning of the year to 37.11% by year-end. The company has successfully expanded its e-commerce, physical retail, and digital sales channels, leveraging strong live-streaming sales performance and precision advertising strategies. Currently, monthly live-streaming sales reach between NT$400 million and NT$500 million, demonstrating strong market momentum.
Yu-Ming Chang emphasized the company’s commitment to deepening the "AI Smart Health" ecosystem by incorporating AI-driven solutions to enhance biomedical data analysis, improving the accuracy of personalized health management. Myson Century is also integrating smart devices, data computing capabilities, and risk management mechanisms to establish a comprehensive service ecosystem covering health management, risk assessment, and financial protection.
The company has secured a majority of board seats at HuaHan Insurance Broker Co., Ltd., and plans to acquire three to four additional insurance brokerage firms through stock swaps or cash transactions to further strengthen its presence in the digital finance sector. As Myson Century's operations expand, the company plans to spin off its financial and biomedical divisions in the future. Meanwhile, its subsidiary, Chowa Biomedical, is aiming for public listing within the next two to three years.
In addition, Myson Century's drone business has begun engaging with clients in Europe and the U.S.. Beyond its existing defense applications, the company is actively expanding into the consumer drone market. Current order negotiations involve batches of over 1,000 units, and if these initiatives progress smoothly, the intelligent drone business could see a significant surge, potentially increasing its revenue contribution from 0.16% to 1%.
Resource: 半導體跨足生技產業 世紀民生聚焦保健、AI技術與精準數據應用
